Rh Disease

National Organization for Rare Disorders, Inc.

Skip to the navigation


It is possible that the main title of the report Rh Disease is not the name you expected. Please check the synonyms listing to find the alternate name(s) and disorder subdivision(s) covered by this report.


  • Congenital Anemia of Newborn
  • Erythroblastosis Fetalis
  • Erythroblastosis Neonatorum
  • Hemolytic Anemia of Newborn
  • Hemolytic Disease of Newborn
  • Icterus Gravis Neonatorum
  • Rh Factor Incompatibility
  • Rh Incompatibility
  • Rhesus Incompatibility

Disorder Subdivisions

  • None

General Discussion

Rh disease or Rh incompatibility (also known as erythroblastosis fetalis) occurs when a woman with Rh-negative blood conceives a child with Rh-positive blood. Red blood cells are destroyed (hemolysis) because of this incompatibility, leading to anemia and other symptoms in the infant. Symptoms vary in severity among affected infants and may include an unusual yellowish coloration of the skin (jaundice); swelling of the chest and abdomen due to the accumulation of fluid (edema); and/or a pale appearance of the skin. In more severe cases, affected infants may have experience life-threatening complications. Rh disease occurs only when a mother's blood is Rh-negative and her baby's blood is Rh-positive.


During the first pregnancy of an Rh-negative woman carrying an Rh-positive fetus, there are rarely any symptoms. However, the risks of sensitization increase with each subsequent pregnancy when the fetus is Rh-positive.

In Rh disease, red blood cells from the fetus cross the placenta and enter into the mother's circulation during pregnancy. This stimulates maternal antibody formation against the Rh factor. These antibodies reach the fetus via the placenta and cause destruction of the fetal red blood cells (hemolysis). This consequently causes anemia in the fetus. To overcome this anemia, the fetal bone marrow releases immature red blood cells (erythroblasts) into the fetal circulation. The hemoglobin from the destroyed red blood cells is broken down to bilirubin, which is cleared from the fetal circulation by crossing the placenta into the mother's blood. After birth, however, bilirubin builds up in the newborn's circulation and high levels of bilirubin may sometimes be deposited in the basal ganglia of the brain causing Kernicterus. (For more information, please choose "kernicterus" as your search term in the Rare Disease Database.)

In women who have developed Rh-sensitization, succeeding pregnancies with Rh incompatibility produce progressively more seriously affected infants, unless treatment with an anti-Rh-gammaglobulin (RhoGAM) is given to the mother within 72 hours after each childbirth or termination of pregnancy. The more severely affected fetuses develop profound anemia in the womb and are delivered with gross edema (swelling) of the entire body (hydrops fetalis). This may be suspected before delivery if excessive fluid around the fetus in the amnion sac (polyhydramnios) is present (detected through x- rays). Sometimes a picture of the fetus in the uterus (amniogram) reveals severe scalp edema.

Newborn infants with Rh disease are extremely pale and may have severe generalized edema, including the presence of liquid in the pleural cavity around the lungs (pleural effusion) and an accumulation of serous fluid in the abdominal cavity (ascites). The liver and spleen are enlarged because of production of red blood cells outside the bone marrow. Congestive heart failure may sometimes occur. Because of anemia and prematurity, lack of oxygen in the lungs (asphyxia) is likely during labor and delivery. The prematurity and asphyxia along with an abnormal decrease of the amount of protein in the blood (hypoproteinemia) may predispose the infant to respiratory distress syndrome (RDS), the signs of which may be difficult to distinguish from those of congestive heart failure.

Less severely affected newborn infants may be anemic, but do not have edema or other signs of hydrops. Others may have little or no anemia at birth. Affected infants usually develop severe hyperbilirubinemia shortly after delivery because of the continuing hemolytic effect of Rh-antibodies that have crossed the placenta.

Succeeding pregnancies tend to produce more seriously affected fetuses. Erythroblastosis can be prevented by injecting the mother with a high-titer anti-Rh-gammaglobulin preparation within 72 hours after delivery to prevent her from developing antibodies.


Rh incompatibility occurs when a woman with Rh-negative blood conceives a child with Rh-positive blood. Red blood cells from the fetus cross the placenta and enter into the mother's circulation stimulating maternal antibody formation against the Rh factor. These antibodies reach the fetus via the placenta and cause destruction of the fetal red blood cells, consequently causing anemia and bilirubin in the fetal blood (jaundice) which makes the infant appear yellow. Rh-negative and -positive blood types are determined by genetic factors.

Affected Populations

Since the introduction of Rh immunoglobulin as a treatment for Rh disease in 1968, the number of babies born with the disorder has dropped dramatically from greater than 20,000 babies per year in the United Sates to approximately 4,000 babies per year.

Rh disease occurs only in infants who have Rh-positive blood and whose mothers have Rh-negative blood. Some clinicians estimate that in the U.S. only about 13% of marriages result in pairing of an Rh-positive man and an Rh-negative woman. They estimate that one in about 27 children born to these couples will suffer from Rh disease.

Standard Therapies

The blood group of the mother can be determined conveniently and with ease. If the mother's blood is found to be Rh-positive, there is no chance of the baby being born with Rh disease. If the mother's blood is found to be Rh-negative, the father's blood group must be determined. If the father's blood group turns out to be Rh-positive, there is a chance that the fetus will be Rh incompatible. In such cases, or if the father is unavailable for testing, a sample of fetal blood is taken in order to determine if Rh incompatibility is present.


All Rh-negative mothers of Rh-positive babies should receive two injections of a biological known as Rh immune globulin (RhIG). The first should be administered at about the 28th week of pregnancy. The second should be given within 72 hours after delivery.

There have been major improvements in the treatment of fetuses with severe Rh disease. Newer treatments involve blood transfusions usually using cordocentesis. This involves using a fine, hollow needle under the guidance of an ultrasound.

An infant with hydrops fetalis or severe erythroblastosis fetalis (without hydrops) due to Rh disease is usually critically ill and should be treated in a perinatal intensive care facility whenever possible. Fetal heart rate should be monitored during labor. If signs of lack of oxygen (asphyxia) occur, or if the infant is severely affected, cesarean section delivery should be performed. The mainstay of treatment is exchange transfusion. This is a blood transfusion using twice the infant's calculated blood volume which removes 85% of the infant's blood, including circulating antibodies, sensitized red blood cells, accumulated bilirubin, and replenishes red blood cells.

Investigational Therapies

Information on current clinical trials is posted on the Internet at www.clinicaltrials.gov. All studies receiving U.S. government funding, and some supported by private industry, are posted on this government web site.

For information about clinical trials being conducted at the NIH Clinical Center in Bethesda, MD, contact the NIH Patient Recruitment Office:

Tollfree: (800) 411-1222

TTY: (866) 411-1010

Email: prpl@cc.nih.gov

For information about clinical trials sponsored by private sources, contact:




Harkness UF, Sipinnato JA. Prevention and management of RhD isoimmunization. Clin Perinatol. 2004;31:721-42.

Bussel JB. Fetal and neonatal cytopenias: what have we learned? Am J perinatol. 2003;20:425-31.

Harrod KS, Hanson L, VandeVusse L, et al. Rh negative status and isoimmunization update: a case-based approach to care. J Perinat Neonatal Nurs. 2-003;17:166-78.

Gottstein R, Cooke RW. Systmeatic review of intravenous immunoglobulin in haemolytic disease of the newborn. Arch Dis Child Fetal Neonatal Ed. 2003;88:F6-10.

Cotorruelo CM, Biondi CS, Garcia Borras S, et al. Clinical aspects of Rh genotyping. Clin Lab. 2002;48:271-81.

Greenough A. The role of immunoglobulinms in neonatal Rhesus haemolytic disease. BioDrugs. 2001;15:533-41.


Salem L. Rh Incompatibility. emedicine. Last Updated: February 7, 2005. 9pp.


Rh Disease. Quick Reference and Fact Sheets. March of Dimes. 2005. 3pp.



NIH/National Heart, Lung and Blood Institute

P.O. Box 30105

Bethesda, MD 20892-0105

Tel: (301)592-8573

Fax: (301)251-1223

Email: nhlbiinfo@rover.nhlbi.nih.gov

Internet: http://www.nhlbi.nih.gov/

National Perinatal Information Center

225 Chapman Street

Suite 200

Providence, RI 02905

Tel: (401)274-0650

Fax: (401)455-0377

Email: web_admin@npic.org

Internet: http://www.npic.org

National Perinatal Association

2000 North Beauregard Street, 6th Floor

Alexandria, VA 22311


Fax: (703)684-5968

Tel: (888)971-3295

Email: npa@nationalperinatal.org

Internet: http://www.nationalperinatal.org

Genetic and Rare Diseases (GARD) Information Center

PO Box 8126

Gaithersburg, MD 20898-8126

Tel: (301)251-4925

Fax: (301)251-4911

Tel: (888)205-2311

TDD: (888)205-3223

Internet: http://rarediseases.info.nih.gov/GARD/

For a Complete Report

This is an abstract of a report from the National Organization for Rare Disorders, Inc.® (NORD). Cigna members can access the complete report by logging into myCigna.com. For non-Cigna members, a copy of the complete report can be obtained for a small fee by visiting the NORD website. The complete report contains additional information including symptoms, causes, affected population, related disorders, standard and investigational treatments (if available), and references from medical literature. For a full-text version of this topic, see http://www.rarediseases.org/search/rdblist.html.